Treatment Group 1 for Ulcerative Colitis

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Ulcerative Colitis+3 More
PF-07054894 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This is a study to learn if the experimental medicine (called PF-07054894) is safe, effective, and how it is processed in adult people with ulcers in the colon.

Eligible Conditions
  • Ulcerative Colitis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Week 12

Week 12
Proportion of participants achieving clinical remission at Week 12
Proportion of participants achieving improvement in endoscopic appearance at Week 12
Proportion of participants with clinical remission at Week 12

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Treatment Group 1
1 of 2
Treatment Group 2
1 of 2
Experimental Treatment
Non-Treatment Group

27 Total Participants · 2 Treatment Groups

Primary Treatment: Treatment Group 1 · Has Placebo Group · Phase 1

Treatment Group 1
Drug
Experimental Group · 1 Intervention: PF-07054894 · Intervention Types: Drug
Treatment Group 2
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PF-07054894
2020
Completed Phase 1
~90

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: week 12

Who is running the clinical trial?

PfizerLead Sponsor
4,260 Previous Clinical Trials
7,104,938 Total Patients Enrolled
27 Trials studying Ulcerative Colitis
419,787 Patients Enrolled for Ulcerative Colitis
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,248 Previous Clinical Trials
4,820,618 Total Patients Enrolled
21 Trials studying Ulcerative Colitis
8,477 Patients Enrolled for Ulcerative Colitis

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a history of inadequate response to, loss of response to, or intolerance to at least one conventional therapy for UC.
You have moderate to severe UC for ≥3 months prior to baseline.
You have a score of 5 to 9 on the modified mayo score.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 19th, 2021

Last Reviewed: October 10th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.